AGP Picks
View all

AGP Executive Report

Last update: 11 hours ago

Cancer Care: The European Commission approved RASONQUE (daraxonrasib), a once-daily oral treatment for adults with metastatic pancreatic cancer after at least one prior systemic therapy. Patient access will depend on national pricing and reimbursement. Lung Cancer: EMA advisers recommended Zybrivo (sintilimab) with chemotherapy as a first-line option for advanced non-squamous lung cancer; European Commission approval is still pending. Rare Conditions: The EU approved Zeydovio (glepaglutide), a twice-weekly treatment for adults with short bowel syndrome, marking the first major European treatment advance for the condition in more than a decade. Regional Health Preparedness: ECDC is preparing to roll out Epi+, a multilingual platform to help nine countries detect and coordinate responses to emerging public-health threats next year. Liechtenstein-Relevant Decisions: EU advisers backed expanded use of Merck’s ENFLONSIA to protect high-risk children from RSV through a second season, and belzutifan plus lenvatinib for advanced kidney cancer after prior immunotherapy. Both recommendations cover Liechtenstein, with European Commission decisions pending.

Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.

AGP Wire

fallback image
Nov. 3, 2026

Genki relaunches Native with month-to-month global health insurance

AGP

fallback image
Sep. 7, 2026

Swiss parabolic flight campaign pivots toward commercial space applications

AGP

fallback image
Jul. 3, 2026

European Commission authorizes CinnaGen’s osteoporosis biosimilar Zandoriah in EU

AGP

fallback image
Jul. 28, 2026

The European releases its Summer 2026 edition

AGP


Perspectify logo Perspectify News

Learn about labels.

Labels
Left-wing Center-left Neutral Public Broadcaster Gov't Institution Center-right Right-wing Pro-Government Gov't Propaganda Indeterminate Press Release Service
filter

Filter

Source Label Filters

All labels are selected. Deselect any labels you want to hide from your feed.

Labels:

Left-wing
Center-left
Neutral
Public Broadcaster
Gov't Institution
Center-right
Right-wing
Pro-Government
Gov't Propaganda
Indeterminate
Press Release Service
From "Healthspans" To Blockchain – A Report From Apex Invest Europe Conference

From "Healthspans" To Blockchain – A Report From Apex Invest Europe Conference

Tanzania invests in agricultural training to bridge classroom knowledge and farmers’ practical needs

Tanzania invests in agricultural training to bridge classroom knowledge and farmers’ practical needs

Investigation launched as first human case of 'brain disease' found in EU country popular with UK tourists

Investigation launched as first human case of 'brain disease' found in EU country popular with UK tourists

EXCLUSIVE: Backed by Google’s first investor, RHISE AI raises €2.66 million to build Europe’s sovereign personal AI

EXCLUSIVE: Backed by Google’s first investor, RHISE AI raises €2.66 million to build Europe’s sovereign personal AI

SFA must row back on all-in Sebastien Pocognoli gamble as Scotland fear ultimate custard pie

SFA must row back on all-in Sebastien Pocognoli gamble as Scotland fear ultimate custard pie


fallback image
Nov. 16, 2026

European Commission Approves Revolution Medicines’ RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

GlobeNewswire, Inc.

fallback image
Nov. 13, 2026

Zealand Pharma announces EU approval of Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome

GlobeNewswire, Inc.

fallback image
Nov. 3, 2026

Genki Relaunches Health Insurance for Nomads

EIN Presswire

fallback image
Oct. 23, 2026

SERB Pharmaceuticals Announces Positive Results from the Post-Authorisation Efficacy Study of Idefirix® (imlifidase) Presented at ASN Kidney Week 2026

GlobeNewswire, Inc.

fallback image
Oct. 15, 2026

Revolution Medicines’ RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer

GlobeNewswire, Inc.

fallback image
Sep. 25, 2026

European Commission grants marketing authorisation for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease

GlobeNewswire, Inc.

More press releases

Video Stories

YouTube video thumbnail: Ukraine Strikes Crimean Bridge in Record Drone Strike on Russia
Play
Ukraine Strikes Crimean Bridge in Record Drone Strike on Russia
YouTube video thumbnail: Europe Hunts for Palantir Alternatives as Militaries Seek to Limit US Dependence
Play
Europe Hunts for Palantir Alternatives as Militaries Seek to Limit US Dependence
YouTube video thumbnail: Discover Affinity Group Publishing
Play
Discover Affinity Group Publishing
YouTube video thumbnail: Burnham Pledges Stronger Ties With Europe a Decade After Brexit
Play
Burnham Pledges Stronger Ties With Europe a Decade After Brexit
YouTube video thumbnail: Britain's Rwanda Plan Failed. Why Are Five EU Countries Reviving the Idea?
Play
Britain's Rwanda Plan Failed. Why Are Five EU Countries Reviving the Idea?

Video Title

Sign up for:

Health Monitor Liechtenstein

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

globe

Explore More

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Health Monitor Liechtenstein

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.